乐观
$74.60
情景价格
$78.840
+2.617 (+3.32%)收盘时
Globus Medical, Inc. is a global musculoskeletal company. The Company provides education and clinical support, and advanced care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. The Company offers a comprehensive portfolio of technologies that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. Its segments include Musculoskeletal Solutions and Enabling Technologies. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, surgical instruments, spinal cord stimulation treatment therapy, and neuromonitoring services, used in an expansive range of spinal, orthopedic and neurosurgical procedures. Its Enabling Technologies are comprised of imaging, navigation and robotics (INR) solutions for assisted surgery, which are advanced computer-assisted intelligent systems designed to enhance a surgeon’s capabilities. The Company also provides digital healthcare solutions.
Currently, Globus Medical Inc is not a strong buy. The stock is priced at $74.65, which is below the average analyst price target of $85 from RBC Capital. The forward P/E ratio of 13.87 indicates it is reasonably valued, but the RSI of 47.94 suggests it is neither overbought nor oversold, indicating a lack of strong momentum. The main risk is the insider selling, which has increased by 389.20% over the last month, signaling potential concerns about the company's future performance.
RBC Capital
$85
2026-10-01
RBC Capital
2026-10-01
目标价
$85
Wells Fargo
$99
2026-08-07
Wells Fargo
2026-08-07
目标价
$99
UBS
$82
2026-07-28
UBS
2026-07-28
目标价
$82
Truist
$100
2026-07-16
Truist
2026-07-16
目标价
$100
BMO Capital
$94
2026-07-08
BMO Capital
2026-07-08
目标价
$94
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

Zacks Adds Five Stocks to Strong Buy List

Ecolab Reports Strong Q2 Performance Amid Cost Concerns

Globus Medical's Excelsius3D Receives CE Mark Approval

Globus Medical Launches CE-Marked Excelsius3D™ Imaging System

Globus Medical Acquires Higgs Boson Health to Enhance Patient Experience
Globus Medical, Inc. is a global musculoskeletal company. The Company provides education and clinical support, and advanced care throughout spine, orthopedic trauma, joint reconstruction, biomaterials and enabling technologies. The Company offers a comprehensive portfolio of technologies that address a variety of musculoskeletal pathologies, anatomies, and surgical approaches. Its segments include Musculoskeletal Solutions and Enabling Technologies. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, surgical instruments, spinal cord stimulation treatment therapy, and neuromonitoring services, used in an expansive range of spinal, orthopedic and neurosurgical procedures. Its Enabling Technologies are comprised of imaging, navigation and robotics (INR) solutions for assisted surgery, which are advanced computer-assisted intelligent systems designed to enhance a surgeon’s capabilities. The Company also provides digital healthcare solutions. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Currently, Globus Medical Inc is not a strong buy. The stock is priced at $74.65, which is below the average analyst price target of $85 from RBC Capital. The forward P/E ratio of 13.87 indicates it is reasonably valued, but the RSI of 47.94 suggests it is neither overbought nor oversold, indicating a lack of strong momentum. The main risk is the insider selling, which has increased by 389.20% over the last month, signaling potential concerns about the company's future performance.
13 analysts cover GMED: 5 rate it Buy, 7 Hold and 1 Sell. The average price target is 101.00.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。